Proton Power Systems
SPECULATIVE BUYLosses at fuel cells developer swelled from £2.4m to £2.8m last year
German fuel cell specialist Proton Power is poised to make a significant step on the road to industrialising its product.
In order to serve the growing demand it claims to be experiencing, the company will in the second half of this year begin mass manufacture of its fuel cells ‘stacks’ and application-specific systems. Production capacity will gradually be increased up to 5,000 units per year.
CEO Thomas Melczer says the company needs to make around €15m to break even, which means selling about 300 stacks per year. In the year to December the company increased revenues by 65% to £1.1m, while losses swelled from £2.4m to £2.8m.
With a number of different projects under its belt, the company hopes their success will encourage follow-up orders. These projects include a passenger ferry to operate on Hamburg's Alster river that was one of the first times the technology has been applied in passenger vessels; a triple-hybrid electric bus in partnership with Skoda; a street-sweeping vehicle made with one of the world’s leading suppliers of municipal vehicles; and a prototype automatic power back-up unit.
The company raised £4m before expenses via two share placings at 10p during the year and Melczer says ‘we’re not running out of cash and we’re not burning so much money – we burned over the year the same as some companies do in a month’. Some £772,000 remained in the bank at the year end but in April, non-executive director and 54% shareholder Dr Faiz Nahab set up a £1.5m convertible loan for Proton through his Roundstone vehicle.
The lowly shares, floated at 80p in 2006, remain for risk-takers only.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £3.75m
PE Forecast: tbc
Share price: 5.25p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
